Immuneering Corp - Class A Common Stock, $0.001 par value per share (IMRX)

Historical Holders from Q3 2021 to Q3 2025

Symbol
IMRX on Nasdaq
Type / Class
Equity / Class A Common Stock, $0.001 par value per share
Shares outstanding
58,762,797
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
26,061,962
Holdings value
$182,434,908
% of all portfolios
0%
Number of holders
69
Number of buys
55
Number of sells
10
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Immuneering Corp - Class A Common Stock, $0.001 par value per share (IMRX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 14% $71,526,603 8,787,052 FMR LLC 30 Sep 2025
Empery Asset Management, LP 8.8% $36,321,285 5,188,755 Empery Asset Management, LP 30 Sep 2025
Zeskind Benjamin J. 13% $5,131,837 3,978,168 BENJAMIN J. ZESKIND 31 Dec 2024
HBM Healthcare Investments (Cayman) Ltd. 5.7% $29,680,915 3,646,304 HBM Healthcare Investments (Cayman) Ltd. 26 Sep 2025
As of 30 Sep 2025 Immuneering Corp - Class A Common Stock, $0.001 par value per share (IMRX) has 69 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 26,061,962 shares of 58,762,797 outstanding shares and own 44% of the company stock as of 30 Sep 2025.

Top 25 institutional shareholders of Immuneering Corp - Class A Common Stock, $0.001 par value per share (IMRX) own 42% of the company based on 13F filings as of 30 Sep 2025

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
FMR LLC 15% 8,787,052 +3876% 0% $61,509,364
Sanofi 4.6% 2,708,559 7.3% $18,959,913
VANGUARD GROUP INC 4.1% 2,415,244 +129% 0% $16,906,708
PRICE T ROWE ASSOCIATES INC /MD/ 3.1% 1,798,782 0% $12,592,000
ExodusPoint Capital Management, LP 2.6% 1,516,833 0.15% $10,617,831
Logos Global Management LP 1.6% 950,000 0.66% $6,650,000
CITADEL ADVISORS LLC 1.6% 943,144 0.01% $6,602,008
BlackRock, Inc. 1.2% 681,185 +61% 0% $4,768,295
Blue Owl Capital Holdings LP 0.94% 550,000 1.2% $3,850,000
GEODE CAPITAL MANAGEMENT, LLC 0.87% 513,665 +123% 0% $3,597,245
Occam Crest Management LP 0.85% 498,498 0% 2.4% $3,489,486
Monashee Investment Management LLC 0.51% 300,000 1% $2,100,000
Burkehill Global Management, LP 0.51% 300,000 0.12% $2,100,000
MORGAN STANLEY 0.5% 294,857 +47% 0% $2,063,999
IRIDIAN ASSET MANAGEMENT LLC/CT 0.47% 275,086 0.76% $1,925,602
SOUTHPORT MANAGEMENT, L.L.C. 0.46% 272,501 +11% 7.9% $1,907,507
MARSHALL WACE, LLP 0.46% 271,304 -53% 0% $1,899,128
Diametric Capital, LP 0.43% 252,193 0.65% $1,765,351
MILLENNIUM MANAGEMENT LLC 0.4% 236,781 +280% 0% $1,657,467
STATE STREET CORP 0.29% 172,864 +78% 0% $1,210,048
Woodline Partners LP 0.26% 150,000 0% $1,050,000
AWM Investment Company, Inc. 0.26% 150,000 0.1% $1,050,000
TD Asset Management Inc 0.25% 145,180 0% $1,016,260
HighTower Advisors, LLC 0.23% 132,459 -2.6% 0% $927,213
UBS Group AG 0.22% 126,402 +2392% 0% $884,814

Institutional Holders of Immuneering Corp - Class A Common Stock, $0.001 par value per share (IMRX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 26,061,962 $182,434,908 +$152,080,309 $7.00 69
2025 Q2 3,829,641 $12,906,115 -$684,756 $3.37 39
2025 Q1 4,498,583 $6,835,562 +$160,622 $1.52 34
2024 Q4 4,238,711 $9,324,244 -$178,795 $2.20 41
2024 Q3 4,355,017 $10,869,922 -$7,529,426 $2.49 38
2024 Q2 9,594,069 $12,279,491 -$9,131,006 $1.28 56
2024 Q1 11,871,552 $34,310,136 -$12,626,272 $2.89 50
2023 Q4 16,130,676 $118,562,071 -$6,299,411 $7.35 52
2023 Q3 16,940,689 $130,106,629 -$5,076,687 $7.68 51
2023 Q2 17,269,886 $175,880,220 +$55,986,352 $10.14 48
2023 Q1 11,823,482 $114,881,649 +$3,891,921 $9.71 33
2022 Q4 11,722,865 $56,864,840 -$4,397,250 $4.85 32
2022 Q3 12,063,607 $172,475,348 -$5,232,579 $14.32 30
2022 Q2 12,129,770 $65,603,270 -$8,956,722 $5.41 31
2022 Q1 13,610,417 $88,108,760 -$3,343,239 $6.47 48
2021 Q4 12,489,185 $199,826,000 +$5,452,789 $16.17 36
2021 Q3 12,105,226 $316,421,451 +$316,421,146 $26.55 38